Who to follow: HealthTech executives
NW
Nicklas Westerholm
CEO · Egetis Therapeutics
Rare diseaseEuropeEmerging
Why follow Nicklas
Leads Egetis, whose Emcitate is approved for MCT8 deficiency.
Writes about
Rare diseaseOrphan drugs
Best for
Readers following rare disease drug development